1. Mason RP, Zhao D, Pacheco-Torres J, et al. Multimodality Imaging of Hypoxia in Preclinical Settings. Q J Nucl Med Mol Imaging 2010; 54(3): 259-80. [
PubMed]
2. Dhani N, Fyles A, Hedley D, et al. The Clinical Significance of Hypoxia in Human Cancers. Semin Nucl Med 2015; 45(2): 110-21. [
Article]
3. Mees G, Dierckx R, Vangestel C, et al. Molecular Imaging of Hypoxia with Radiolabelled Agents. Eur J Nucl Med Mol Imaging 2009; 36(10): 1674-86. [
Article]
4. Krohn KA, Link JM, Mason RP. Molecular Imaging of Hypoxia. J Nucl Med 2008; 49: 129S-48S. [
PubMed]
5. Span PN, Bussink J. Biology of Hypoxia. Semin Nucl Med 2015; 45(2): 101-9. [
Article]
6. Langen KJ, Eschmann SM. Correlative Imaging of Hypoxia and Angiogenesis. J Nucl Med 2008; 49(4): 515-6. [
Article]
7. Linder KE, Chan Y-W, Cyr JE, et al. TcO (PnA. O-1-(2-nitroimidazole))[BMS-181321], A New Technetium-containing Nitroimidazole Complex for Imaging Hypoxia: Synthesis, Characterization, and Xanthine Oxidase-catalyzed Reduction .J Med Chem 1994; 37(1): 9-17. [
PubMed]
8. Nunn A, Linder K, Strauss HW. Nitroimidazoles and Imaging Hypoxia. Eur J Nucl Med 1995; 22(3): 265-80. [
Article]
9. Le QT, Courter D. Clinical Biomarkers for Hypoxia Targeting. Cancer Metastasis Rev 2008; 27(3): 351-62. [
Article]
10. Varia MA, Calkins-Adams DP, Rinker LH, et al. Pimonidazole: A Novel Hypoxia Marker for Complementary Study of Tumor Hypoxia and Cell Proliferation in Cervical Carcinoma. Gynecol Oncol 1998; 71(2): 270-7. [
Article]
11. Melo T, Tunggal JK, Ballinger JR, et al. Flux Through Multicellular Layers of A Technetium-99m-Nitroimidazole for Imaging Hypoxia. Cancer Biother Radiopharm 2002; 17(5): 515-26. [
PubMed]
12. Rezaeianpour S, Mosayebnia M, Bozorgi AH, et al. Design, Synthesis and Radiolabeling of Peptide GPRPILE with 18FDG as Fibrin Imaging Agent for Thrombosis Detection. Iran South Med J 2018; 21(3): 228-41. [
Article]
13. Liu S, Edwards DS. 99mTc-labeled Small Peptides As Diagnostic Radiopharmaceuticals. Chem Rev 1999; 99(9): 2235-68 [
Article]
14. Klimentzou P, Beck A, Varvarigou A, et al. Solid‐phase Synthesis of a Peptide Derivative of Thymosin alpha1 and Initial Studies on its 99mTc‐Radiolabelling. Chem Biol Drug Des 2007; 70: 40-6 [
Article]
15. Couture F, Levesque C, Dumulon-Perreault V, et al. PACE4-based Molecular Targeting of Prostate Cancer Using An Engineered 64 Cu-radiolabeled Peptide Inhibitor. Neoplasia 2014; 16(8): 634-43 [
Article]
16. Karachaliou CE, Liolios C, Triantis C, et al. Specific in Vitro Binding of Prothymosin alpha on Human Neutrophils. Int J Pharm 2015; 486(1-2):1-12. [
Article]
17. Hausner SH, Bauer N, Hu LY, et al. The Effect of Bi-Terminal PEGylation of an Integrin αvβ6–Targeted 18F Peptide on Pharmacokinetics and Tumor Uptake. J Nucl Med 2015; 56(5): 784-90. [
Article]
18. Zhang X, Su ZF, Ballinger JR, et al. Targeting Hypoxia in Tumors Using 2-nitroimidazoles with Peptidic Chelators for Technetium-99m: Effect of Lipophilicity. Bioconjug Chem 2000; 11: 401-7. [
Article]
19. Rezaeianpour S, Bozorgi AH, Moghimi A, et al. Synthesis and Biological Evaluation of Cyclic [99mTc]-HYNIC-CGPRPPC as a Fibrin-Binding Peptide for Molecular Imaging of Thrombosis and Its Comparison with [99mTc]-HYNIC-GPRPP. Mol Imaging Biol 2017; 19(2):256-64 [
Article]
20. Mosayebnia M, Hajiramezanali M, Shahhosseini S, et al. Docking, synthesis, in-vitro evaluation, and optimization of reaction conditions for direct radiolabeling of CGPRPPC with technetium-99m through the GAGG sequence. Nucl Med Commun 2018; 39(11): 976-82. [
PubMed]
21. Rasey JS, Koh W-J, Grierson JR, et al. Radiolabeled Fluoromisonidazole As Imaging Agent for Tumor Hypoxia. Int J Radiat Oncol Biol Phys 1989; 17(5): 985-91. [
Article]